Epsilogen Secures £12.5 Million for Cancer Immunotherapy
Epsilogen, a pioneering company based in London, UK, has gained significant attention for its innovative approach to cancer treatment through the development of immunoglobulin E (IgE) antibodies. Recently, the company successfully raised £12.5 million in a Series B funding round. This latest infusion of capital has brought the total funding raised by Epsilogen to an impressive £43.25 million. The funding round saw participation from prominent investors including British Patient Capital, Novartis Venture Fund, Epidarex Capital, 3B Future Health Fund, and ALSA Ventures, highlighting the confidence that the investment community has in the company’s mission and potential for growth.
Under the leadership of CEO Tim Wilson, Epsilogen is on a quest to harness the natural functions of IgE antibodies, which play a crucial role in immune defense against certain parasites, for the treatment of solid tumors.
The inherently potent nature, improved accessibility to tumor tissues, and prolonged half-life of these antibodies make them an appealing option for cancer therapies. Epsilogen's lead product candidate, MOv18 IgE, has made history as the first therapeutic IgE antibody to enter clinical trials, and the encouraging results from a completed Phase I trial indicate that MOv18 IgE is not only safe but also well-tolerated, with promising early signs of clinical activity.
Furthermore, Epsilogen has achieved a significant milestone by successfully completing large-scale Good Manufacturing Practice (GMP) manufacturing of MOv18 IgE, marking a first in the development of IgE antibodies. The company is preparing to initiate a Phase Ib trial focused on patients suffering from platinum-resistant ovarian cancer later this year. In addition to MOv18 IgE, Epsilogen is committed to developing a robust pipeline of IgE therapies in oncology, which includes proprietary innovations such as IgE bispecifics and unique IgE/IgG combination antibody molecules (IgEGs) that boast enhanced functionality. Since its inception in 2017 as a spin-out from King’s College London, Epsilogen has attracted investment from notable venture capital firms including Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures, and Schroders Capital, underscoring its rapid growth and impact in the biotechnology sector.
They've invested in Epsilogen
Get to know these Biotech investors
| # | Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|---|
1 |  British Patient Capital | 10 investment(s) investment(s) | 25 contacts contacts | |||
2 |  Novartis Venture Fund | 3 investment(s) investment(s) | more info | |||
3 |  Epidarex Capital | 4 investment(s) investment(s) | more info | |||
4 |  3B Future Health Fund | 1 investment(s) investment(s) | more info | |||
5 |  ALSA Ventures | 1 investment(s) investment(s) | more info |
Click here for a full list of 6,528+ startup investors in the UK